Sanofi Consumer Healthcare India Limited has announced the closure of its trading window effective October 1, 2026. This measure is implemented in compliance with the company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons.

The trading window will remain closed until 48 hours after the announcement of the company's unaudited standalone financial results for the quarter and nine months ended September 30, 2026. This period covers the second quarter of the fiscal year 2026-27 (Q2FY27).

Regulatory Compliance and Timeline

The decision was communicated to BSE Limited and National Stock Exchange of India Limited on September 28, 2026. The company stated that the closure is necessary for the purpose of declaring the upcoming financial results. Designated persons are prohibited from trading in the company's securities during this blackout period.

The notice was signed by Nikunj Kumar Savaliya, Company Secretary and Compliance Officer, confirming adherence to internal regulatory frameworks.

Sanofi Consumer Healthcare India Limited reported a 13.18% year-on-year increase in net profit to ₹688 million for the quarter ended June 30, 2026, driven by a 6.84% rise in revenue from operations to ₹2,420 million. The company’s Board of Directors approved the unaudited financial results on July 28, 2026, confirming continued operational stability and profitability growth in the consumer healthcare segment. The results were subsequently published in Business Standard and Sakal on July 30, 2026, as required by regulatory norms.

The financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015. The Audit Committee reviewed the figures before formal approval by the Board. Sanofi Consumer Healthcare India Limited disclosed that it has no subsidiaries, associates, or joint ventures as of June 30, 2026.

Financial Performance

Total income from operations grew to ₹2,420 million in Q1FY27, up from ₹2,265 million in the corresponding period last year. Net profit before tax, exceptional, and extraordinary items stood at ₹919 million, compared to ₹723 million in Q1FY26. After accounting for taxes and other items, the net profit after tax reached ₹688 million, an improvement from ₹607 million in the previous year.

For the half-year ended June 30, 2026, total income from operations aggregated to ₹4,768 million, a significant jump from ₹4,043 million in H1FY26. Net profit after tax for the half-year was ₹1,366 million, compared to ₹1,107 million in the prior year period.

What the Numbers Show

The divergence between the 27.11% growth in pre-tax profits and the 6.84% growth in revenue suggests improved operational efficiency or favorable tax adjustments during the quarter. Basic and diluted earnings per share (EPS) rose to ₹29.87 from ₹26.36 in the same quarter last year, reflecting the accretive impact of higher net earnings on shareholder value. The equity share capital remained unchanged at ₹230 million.